Answers are grounded in this paper and cite their sources.
Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark'' by Pollock and Muduma [1].The authors present a budget impact analysis (BIA) comparing two intravenous (IV) iron treatments, iron isomaltoside (IIM) and ferric carboxymaltose (FCM) in the treatment of iron deficiency anemia (IDA) associated with inflammatory bowel disease (IBD).
No takes yet. Share an insight, caveat, or question.
Aksan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: